This inventor holds 1 USPTO granted patent. Top assignee: Kissei Pharmaceutical Co., Ltd.. Active years: 1995.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1995
Title: Toshikazu Yazaki: Innovator in Indoline Compounds
Introduction
Toshikazu Yazaki is a notable inventor based in Nagano, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on indoline compounds. His research focuses on developing therapeutic agents that address specific medical conditions.
Latest Patents
Yazaki holds a patent for 1,5,7-trisubstituted indoline compounds and their salts. These compounds are represented by a specific chemical formula, wherein R denotes various aliphatic and aromatic groups. The compounds exhibit a selective suppressive action on urethral contractions, making them useful for treating dysuria with minimal hypotension, including postural hypotension. This patent highlights Yazaki's commitment to advancing medical treatments through innovative chemical solutions.
Career Highlights
Yazaki is associated with Kissei Pharmaceutical Co., Ltd., where he continues to contribute to pharmaceutical research and development. His work has been instrumental in creating new therapeutic options for patients suffering from urinary disorders. His dedication to innovation in the pharmaceutical industry is evident through his research and patent achievements.
Collaborations
Yazaki has collaborated with notable colleagues such as Makio Kitazawa and Ryoichi Yamagishi. These partnerships have fostered a collaborative environment that enhances the research and development process, leading to significant advancements in their field.
Conclusion
Toshikazu Yazaki's contributions to the development of indoline compounds demonstrate his innovative spirit and commitment to improving healthcare solutions. His work continues to impact the pharmaceutical industry positively, paving the way for new therapeutic agents.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile